Inference of neoantigen immunogenicity and anticancer efficacy
[by Yu, Suin] CG Invites announced on May 23 that an abstract detailing research findings from its AI-driven anticancer vaccine platform, ‘imNEO’, was presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO 2025), the world’s largest oncology conference.
The research abstract, titled ‘imNEO: High-accuracy neoantigen prediction through 메이저 바카라 사이트-based integrated analysis of multiple immunogenicity-related factors,’ highlights that the platform’s excellent capability to accurately identify ‘neoantigens,’ key components in the development of personalized anticancer vaccines, has been reaffirmed through the integration and analysis of various immune-related indicators using 메이저 바카라 사이트.
The research team developed the ‘imNEO’ prediction model by integrating seven machine learning algorithms tr메이저 바카라 사이트ned on a dataset encompassing 30 immunogenicity-related factors. This model demonstrated up to 15.6% higher prediction accuracy compared to existing technologies, with average positive prediction rates of 85% for the top 10 neoantigens and 70% for the top 20.
In a colon cancer animal model experiment, 76% of the neoantigens selected by ‘imNEO’ induced strong interferon gamma (IFN-γ) secretion, indicating a high immune response. Significant anticancer effects were also observed, as evidenced by tumor growth inhibition and antibody production tests.
“The acceptance of our abstract by ASCO means that ‘imNEO’ possesses exceptional technological competitiveness in the global precision medicine landscape,” stated Oh Soo-yeon, Co-CEO of CG Invites. “We anticipate that our 메이저 바카라 사이트 neoantigen prediction platform will significantly advance the development of personalized anticancer vaccines to the next level.”